Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

被引:61
作者
Santoro, M
Carlomagno, F
机构
[1] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy
[2] CNR, Inst Endocrinol & Expt Oncol G Salvatore, Naples, Italy
来源
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2006年 / 2卷 / 01期
关键词
BRAF; inhibitor; kinase; RET; thyroid cancer;
D O I
10.1038/ncpendmet0073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Molecular targeting of protein kinases is a new paradigm in the treatment of cancer. The clinical efficacy of low-molecular weight inhibitors of ABL, stem-cell growth-factor receptor, and the epidermal growth factor receptor in different tumor types is witness to the power of this approach. The presence of activating mutations of a kinase, or an increased gene copy number, might anticipate tumor responsiveness to its targeting. Thyroid cancer is the most prevalent endocrine malignancy and is frequently associated with the oncogenic conversion of two specific protein kinases, RET and BRAF. Small-molecule inhibitors of both kinases have already reached the clinical testing stage. Protein kinases other than RET and BRAF are also being evaluated for their potential in thyroid-cancer treatment.
引用
收藏
页码:42 / 52
页数:11
相关论文
共 73 条
[1]  
Ain KB, 1999, SEMIN SURG ONCOL, V16, P64, DOI 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.3.CO
[2]  
2-L
[3]   The GDNF family: Signalling, biological functions and therapeutic value [J].
Airaksinen, MS ;
Saarma, M .
NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) :383-394
[4]   Aurora kinases: shining lights on the therapeutic horizon? [J].
Andrews, PD .
ONCOGENE, 2005, 24 (32) :5005-5015
[5]   Raf: A strategic target for therapeutic development against cancer [J].
Beeram, M ;
Patnaik, A ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6771-6790
[6]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[7]  
Bollag Gideon, 2003, Curr Opin Investig Drugs, V4, P1436
[8]   17-allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels [J].
Braga-Basaria, M ;
Hardy, E ;
Gottfried, R ;
Burman, KD ;
Saji, M ;
Ringel, MD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2982-2988
[9]   Molecular diagnosis of multiple endocrine neoplasia Type 2 [J].
Bugalho, MJ ;
Domingues, R ;
Sobrinho, L .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2003, 3 (06) :769-779
[10]  
Carlomagno F, 2002, CANCER RES, V62, P7284